Superior execution in consumer wellnessexports drives beat on 2Q estimates

Company
06 Nov 2024
5 Min read 
  • Mankind Pharma's 2QFY25 performance exceeded expectations.
  •  Sales grew 13.6% YoY, driven by strong domestic and export business.
  •  Gross margin expanded by 200bp to 71.6% due to product mix and lower raw material prices.
  •  Management expects 25-26% EBITDA margin for FY25.
  •  Mankind is focusing on increasing share of chronic therapies and expanding consumer wellness brands.
  •  The company is working on multiple growth drivers and expects 18% earnings CAGR over FY25-27.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority